Clearmind announces IRB approval for FDA first-in-human trial of CMND-100

Clearmind Medicine announced it has received Institutional Review Board, IRB, approval from one of its clinical sites in the U.S. for part A of its Phase I/IIa clinical trial in the United States for treating patients suffering from alcohol use disorder, AUD. The multinational, multi-center trial will assess the safety, tolerability, and pharmacokinetics of Clearmind’s MEAI-based treatment, CMND-100. In addition to Johns Hopkins University, Maryland, USA, the trial will also take place at Yale School of Medicine, Connecticut, USA and IMCA Center in Ramat Gan, Israel. The Company has already secured FDA approval for its Investigational New Drug application to conduct the trial in the U.S., as well as approval from the Israeli Ministry of Health. IMCA’s IRB approval has also been granted.